Beaumont Financial Advisors LLC Sells 5,128 Shares of Pfizer Inc. (NYSE:PFE)

Beaumont Financial Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,403 shares of the biopharmaceutical company’s stock after selling 5,128 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Pfizer were worth $587,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Front Street Capital Management Inc. lifted its holdings in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares during the last quarter. Castleview Partners LLC lifted its holdings in Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares during the last quarter. United Bank lifted its holdings in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the last quarter. Compton Capital Management Inc. RI lifted its holdings in Pfizer by 0.5% during the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after purchasing an additional 300 shares during the last quarter. Finally, GHP Investment Advisors Inc. lifted its holdings in Pfizer by 2.4% during the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Pfizer stock opened at $25.99 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52 week low of $25.23 and a 52 week high of $40.37. The stock has a market capitalization of $147.17 billion, a P/E ratio of 72.19, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The stock has a fifty day moving average of $27.11 and a 200-day moving average of $28.68.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the firm earned $1.14 EPS. Pfizer’s revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.